Le Lézard
Classified in: Health
Subject: PLW

Argentum Pharmaceuticals and Eli Lilly Settle Patent Dispute Over CIALIS®


NEW YORK, Aug. 22, 2017 /PRNewswire/ -- Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement and license agreement with Eli Lilly and Company related to Argentum's generic version of CIALIS® (tadalifil).

Argentum Pharmaceuticals. Balancing the rights of pharmaceutical innovators and consumers. (PRNewsFoto/Argentum Pharmaceuticals)

The agreement generally provides that Argentum may commence marketing its generic product no earlier than September 27, 2018. The specific date on which Argentum may launch its generic product and other details concerning the settlement have not been disclosed.

CIALIS® is a registered trademark of Eli Lilly and Company.

SOURCE Argentum Pharmaceuticals LLC


These press releases may also interest you

at 06:15
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Overall 8.46 Average Revised Venous Clinical Severity Score (rVCSS) Improvement Per Patient for Patients Showing Clinical Meaningful Benefit (rVCSS Improvement ≥ 3 Points) including:9.29 Points for Patients at the Two-Year Milestone8.08 Points...

at 06:10
Thermo Fisher Scientific to Host Investor Day
Thermo Fisher Scientific Inc. , the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City. The format will feature presentations by members of Thermo Fisher...

at 06:05
Thermo Fisher Scientific Reports First Quarter 2024 Results
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP...

at 06:05
Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's...

at 06:05
Revvity Unveils a New Era of Automated Tuberculosis Testing
Revvity, Inc. today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the...

at 06:00
Esthetic Medspa Portland Offers Aesthetic Services in State-of-the-Art Downtown Facility
Great skin begins at Esthetic Medspa Portland, where patients receive premium care in a state-of-the-art facility. Guests can peruse the clinic's many services on...

More news about Health...


News published on and distributed by: